MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells
Authors
Keywords
Gastric cancer, Cell motility, Small interfering RNAs, Transfection, Entropy, Cancer treatment, Cell proliferation, Tyrosine kinase inhibitors
Journal
PLoS One
Volume 14, Issue 9, Pages e0223225
Publisher
Public Library of Science (PLoS)
Online
2019-09-27
DOI
10.1371/journal.pone.0223225
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations
- (2018) Hidejiro Torigoe et al. CANCER SCIENCE
- Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer
- (2018) Takahiro Yoshioka et al. CANCER SCIENCE
- Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor
- (2018) Hyun Jeong Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
- (2018) Zuhua Chen et al. Journal of Hematology & Oncology
- MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
- (2018) Han S. Kim et al. JOURNAL OF SURGICAL ONCOLOGY
- Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
- (2018) Simone Keller et al. Molecular Oncology
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
- (2018) Francisco Sanchez-Vega et al. Cancer Discovery
- MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
- (2017) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer
- (2017) Cunxi Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
- (2016) Chi Hoon Park et al. BMC CANCER
- cMET Exon 14 Skipping: From the Structure to the Clinic
- (2016) Nele Van Der Steen et al. Journal of Thoracic Oncology
- Clinical impact of tumour biology in the management of gastroesophageal cancer
- (2016) Florian Lordick et al. Nature Reviews Clinical Oncology
- The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
- (2016) Laurence Booth et al. Oncotarget
- Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients
- (2015) Nozomu Fuse et al. Gastric Cancer
- Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).
- (2015) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.
- (2015) Eunice Lee Kwak et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- Dynamic Reprogramming of Signaling Upon Met Inhibition Reveals a Mechanism of Drug Resistance in Gastric Cancer
- (2014) A. Z. Lai et al. Science Signaling
- Met as a therapeutic target in HCC: Facts and hopes
- (2013) Silvia Giordano et al. JOURNAL OF HEPATOLOGY
- Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET
- (2013) Y. Y. Janjigian et al. JOURNAL OF NUCLEAR MEDICINE
- Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
- (2013) Gang Chen et al. PLoS One
- Targeting tumor cell motility as a strategy against invasion and metastasis
- (2013) Alan Wells et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines
- (2012) JULIA KNEISSL et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines
- (2012) Stefan Heindl et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
- (2012) C.-T. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion
- (2010) Yoshinari Asaoka et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started